Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.
Acute myeloid leukemia (AML) is a rare, fast-growing cancer that starts in the bone marrow. The disease promotes the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback